NYSEARCA:GERM Amplify Treatments, Testing and Advancements ETF (GERM) Price, Holdings, & News $19.16 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHoldings About Amplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GERM alerts:Sign Up Key Stats Today's Range$19.16▼$19.1650-Day Range$19.16▼$19.1652-Week Range$15.67▼$20.20VolumeN/AAverage Volume1,891 shsMarket Capitalization$10.54 millionAssets Under Management$9.67 millionDividend Yield0.73%Net Expense Ratio0.68%Aggregate RatingN/A ETF OverviewThe ETFMG Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is managed by ETF Managers Group.Read More… Amplify Treatments, Testing and Advancements ETF ExpensesTypeGERMTheme ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.68%0.57%0.56%0.51%0.53%Other Expenses0.00%0.57%0.50%0.57%0.53%Total Expense0.68%0.72%0.72%0.73%0.71%Fee Waiver0.00%-0.72%-0.50%-0.66%-0.56%Net Expense0.68%0.60%0.62%0.58%0.60% Receive GERM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amplify Treatments, Testing and Advancements ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address GERM ETF News HeadlinesAmplia Therapeutics Advances Cancer Drug TrialOctober 30, 2024 | markets.businessinsider.comMpox Variant Sparks Global Concern As Europe, China Ramp Up ScreeningAugust 19, 2024 | benzinga.comEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. Should you sit on the sideline while this is happening?February 22, 2025 | Colonial Metals (Ad)Amplify ETFs to Liquidate Three ETFsAugust 15, 2024 | finance.yahoo.comTHNR Amplify Weight Loss Drug & Treatment ETFAugust 1, 2024 | seekingalpha.comETFMG Treatments Testing and Advancements ETFFebruary 11, 2024 | thestreet.comSee More Headlines GERM ETF - Frequently Asked Questions How have GERM shares performed this year? Amplify Treatments, Testing and Advancements ETF's stock was trading at $19.1577 at the start of the year. Since then, GERM shares have increased by 0.0% and is now trading at $19.1577. View the best growth stocks for 2025 here. How do I buy shares of Amplify Treatments, Testing and Advancements ETF? Shares of GERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amplify Treatments, Testing and Advancements ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amplify Treatments, Testing and Advancements ETF investors own include Moderna (MRNA), PayPal (PYPL), Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ), Walt Disney (DIS), NVIDIA (NVDA), Tesla (TSLA) and AbbVie (ABBV). Fund Details IssuerAmplify Fund NameAmplify Treatments, Testing and Advancements ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:GERM Inception Date6/17/2020 Fund ManagerCharles Ragauss, Qiao Duan WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkPrime Treatments, Testing and Advancements Index CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings2 Fund Statistics Assets Under Management$9.67 million Average Daily Volume$0.00 Discount/Premium-0.18% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorAmplify Investments LLC CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest100 shs Miscellaneous Outstanding Shares550,000Beta1.08 Creation Unit50,000 Creation Fee$300.00 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Top 4 GERM HoldingsInvesco Government & Agency Portfolio 12/31/2031Holding Weight: 99.70%Cash & OtherHolding Weight: 0.30%AstraZeneca PLCHolding Weight: 0.00%Gurnet Point Capital LLCHolding Weight: 0.00%Full Holdings Details This page (NYSEARCA:GERM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplify Treatments, Testing and Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Amplify Treatments, Testing and Advancements ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.